论文部分内容阅读
【目的】探讨低剂量分次放疗（LD‐FRT ）联合化疗治疗复发或进展恶性胶质瘤（GBM ）的疗效。【方法】收集经放射疗法结合替莫唑胺（RT／TMZ）治疗至少3个月后复发或进展的GBM 患者28例，根据不同病情分别采用福莫司汀（FTM）加顺铂（CDDP）联合LD‐FRT ；或替莫唑胺（TMZ）联合LD‐FRT。观察临床疗效、毒性、生存率、统计无疾病进展时间（PFS）和中位生存时间（OS）情况。【结果】28例患者均完成低剂量分次放疗联合化疗，其中18例TMZ联合LD‐FRT治疗，10例CDDP和FTM 联合LD‐FRT 治疗；平均放疗剂量为8．0（2．4～21．6）Gy ，平均CVT 49．01（7．24～143．59）cm3。所有毒性反应均为可复性，未见治疗相关的死亡。3．6％（1／28）完全有效，10．7％（3／28）部分有效，25％（7／28）患者治疗结束后病情稳定至少8周，60．7％（17／28）疾病进展；患者的临床受益率为39．3％（11／28）。平均PFS为5个月，6和12个月PFS的患者分别为35．7％（10／28）和10．7％（3／28）；平均OS为8个月，6个月和12个月OS的患者分别为60．7％（17／28）和22．4％（6／28）。【结论】LD‐FRT联合TMZ或FTM加CDDP方案可作为复发或进展GBM患者姑息性治疗方案之一，值得临床推广应用。“,”[Objective] To evaluate the safety and efficacy of low‐dose fractionated radiotherapy (LD‐FRT) plus temozolomide (TMZ) or fotemustine (FTM) plus cisplatin (CDDP) for recurrent or progressive glioblastoma (GBM) .[Methods] A total of 28 patients with magnetic resonance imaging (MRI) evidence of recurrent or progressive GBM after radiotherapy plus TMZ (RT/TMZ) treatment of at least 3 months .They received two different regiments of LD‐FRT plus chemotherapy (TMZ or FTM and CDDP) .And compliance , treatment‐related toxicity ,clinical response ,survival analysis ,progression‐free survival (PFS) and overall survival (OS) were evaluated .[Results] The median total dose of LD‐FRT delivered was 8 (2 .4~21 .6) Gy ;LD‐FRT plus TMZ ( n =18) and CDDP plus FTM ( n =10) .The median CVT was 49 .01 (7 .24~143 .59) cm3 .All toxicities were reversible and no treatment‐related death was observed .One patient (3 .6% ) showed complete response ,3 (10 .7% ) partial response ,7 (25% ) stable disease for at least 8 weeks after the end of treatment and 17 (60 .7% ) progressive disease .The overall rate of clinical benefit was 39 .3% (11/28) .The median PFS was 5 months with 6 and 12‐month PFS (PFS‐6 and PFS‐12) of 35 .2 and 10 .9% respectively ;Median OS was 8 months with 6 and 12‐month survival rates (OS‐6 and OS‐12) of 61 .3 and 21 .1% respec‐tively .[Conclusion]LD‐FRT plus chemotherapy may represent a new well‐tolerated palliative schedule for pa‐tients with recurrent or progressive disease .